Calamos Advisors
RVMD icon

Calamos Advisors’s Revolution Medicines RVMD Stock Holding History

Calamos Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69M Buy
19,711
+4,248
+27% +$620K 0.01% 591
2026
Q1 		$1.5M Buy
15,463
+3,003
+24% +$303K 0.01% 711
2025
Q4 		$992K Buy
+12,460
New +$817K ﹤0.01% 696

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Calamos Advisors's RVMD Position: Q2 2026 in Review

Calamos Advisors increased its Revolution Medicines (RVMD) stake by 27% in Q2 2026, buying an estimated $620K and bringing the position to 19,711 shares worth $3.69M. The position accounts for 0.01% of the portfolio, ranked #591.

Calamos Advisors first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Calamos Advisors held 19,711 shares of Revolution Medicines worth $3.69M as of Q2 2026.
  • Calamos Advisors bought 4,248 Revolution Medicines shares in Q2 2026, an estimated $620K.
  • Revolution Medicines made up 0.01% of Calamos Advisors's portfolio in Q2 2026, its #591 holding.
  • Calamos Advisors first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.